Peptide Registry

GHRP-6

$17.00

  • Contents: GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂)
  • Form: Lyophilized powder
  • Purity: >99%
Quantity Discount Price
1 - 3 - $17.00
4 - 7 10% $15.30
8 + 18% $13.94
SKU: N/A Category: Brand:

Description

GHRP-6 is a synthetic hexapeptide growth hormone secretagogue, the original first-generation GHRP from which the broader peptide class takes its name. GHRP-6 activates the full pharmacological footprint of ghrelin receptor stimulation, including potent orexigenic signaling through hypothalamic NPY/AgRP pathways and significant ACTH and cortisol co-stimulation alongside GH release. Researchers studying the full scope of ghrelin receptor biology select GHRP-6 specifically because of this broad receptor engagement, not despite it.

Chemical Information

  • Chemical Name: GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2)
  • Also Known As: Growth Hormone Releasing Peptide-6
  • Compound Class: Synthetic hexapeptide; growth hormone secretagogue (ghrelin/GHS-receptor agonist)
  • Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
  • Molecular Formula: C46H56N12O6
  • Molecular Weight: 872.99 g/mol
  • CAS Number: 87616-84-0

Applications

  • GH-axis secretagogue mechanism research. GHRP-6 binds and activates the growth hormone secretagogue receptor (GHS-R1a). This is the same receptor targeted by endogenous ghrelin, triggering a Gq/phospholipase-C-mediated calcium signaling cascade in pituitary somatotrophs; it is the original, most extensively studied GHRP-family member and is frequently compared against GHRH-receptor agonists (Sermorelin, Tesamorelin, CJC-1295) to isolate which downstream GH-axis effects depend on each distinct receptor pathway
  • GHRP/GHRH synergy research. Co-administration protocols pairing GHRP-6 with a GHRH analog are a standard experimental design for studying the synergistic amplification of GH pulse amplitude that occurs when both receptor pathways are activated together
  • Appetite and orexigenic signaling research. GHRP-6 produces the strongest appetite-stimulating effect of the GHRP family at comparable doses. This is thanks to GHS-R1a activation in hypothalamic feeding-control circuits outside the pituitary, making it a standard tool for studying ghrelin-receptor-mediated feeding behavior separate from its GH-releasing activity
  • Comparative GHRP-selectivity research. GHRP-6 shows more pronounced appetite and cortisol/prolactin co-release than newer-generation secretagogues such as Ipamorelin. Therefore, it is used as the non-selective comparator in research characterizing receptor-selectivity differences across the GHRP class

Storage and Handling

Store lyophilized powder at -20C for long-term stability, or at 2-8C for short-term use. Protect from heat, moisture, and direct light. Reconstitute with bacteriostatic or sterile water immediately before use; store reconstituted solution at 2-8C and use promptly, avoiding repeated freeze-thaw cycles.

Compliance Notice

GHRP-6 is for laboratory research use only. It is not for human or veterinary use and carries no therapeutic, diagnostic, or clinical indication. This product has not been evaluated by the FDA. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.

Frequently Asked Questions

What is GHRP-6?

GHRP-6 is the original first-generation synthetic hexapeptide growth hormone secretagogue, activating GHSR-1a through Gq/11-mediated intracellular calcium signaling to stimulate GH release from anterior pituitary somatotrophs. It is studied for its broad ghrelin receptor pharmacology, including potent orexigenic signaling through hypothalamic NPY/AgRP pathways and ACTH/cortisol co-stimulation, for which newer, more selective GHRPs were designed to reduce.

Why would a researcher choose GHRP-6 over more selective GHRPs?

More selective GHRPs like Ipamorelin and GHRP-2 were developed specifically to isolate GH release from the broader ghrelin receptor pharmacology that GHRP-6 produces. Researchers choose GHRP-6 when that broader pharmacology is the research target — when the study is designed to examine orexigenic signaling, NPY/AgRP pathway activity, or the interaction between ghrelin receptor stimulation and hypothalamic-pituitary-adrenal axis function. The "confounds" that make GHRP-6 less suitable for pure GH studies are the experimental variables in appetite and stress axis research.

How does GHRP-6's CD36 interaction relate to its research applications?

CD36 is a scavenger receptor expressed in cardiac, adipose, and immune cell populations. GHRP-6's documented CD36 activity — shared with Hexarelin but absent from more selective GHRPs — connects it to research models examining cytoprotective and cardioprotective signaling independent of its GH secretagogue properties. Researchers studying GHSR-1a biology specifically use Ipamorelin or GHRP-2; those examining how ghrelin receptor agonism interacts with peripheral scavenger receptor biology include GHRP-6 in designs where CD36-mediated signaling is a relevant variable.